Preclinical Development of VIS171 – A Novel Modified IL-2 Safely and Selectively Upregulates Regulatory T Cells to Treat Autoimmune Diseases
September 6, 2024 | Promise of Interleukin-2 Therapy Conference
John J. O’Neil, Greg J. Babcock, Zach Shiver, David Oldach, Susan Sloan